RPO LLC’s Allogene Therapeutics ALLO Stock Holding History

RPO LLC’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,787	Closed	-$31.5K	–	44
2024 Q4	$31.5K	Buy	+14,787	New	+$36.5K	0.03%	70
2024 Q1	–	Sell	-14,333	Closed	-$46K	–	49
2023 Q4	$46K	Buy	+14,333	New	+$40.7K	0.07%	81

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RPO LLC's ALLO Position: Q1 2025 in Review

RPO LLC sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 14,787 shares — an estimated $31.5K sold.

RPO LLC first reported a position in ALLO in Q4 2023 and held it in 2 quarters. The position peaked at $46K in Q4 2023. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

RPO LLC reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
RPO LLC sold 14,787 Allogene Therapeutics shares in Q1 2025, an estimated $31.5K.
RPO LLC first reported a position in Allogene Therapeutics in Q4 2023 and held it in 2 quarters.
RPO LLC's Allogene Therapeutics position peaked at $46K in Q4 2023.
170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on RPO LLC's 13F filing for Q1 2025, filed 13 May 2025.